Xinyu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xinyu Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Bowen Tang
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China
1 shared publicationChenxiao Tu
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China
1 shared publicationDongyao Zhao
Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University No. 1 Jianshe East, Zhengzhou, Henan, China
1 shared publicationHan Yang
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University No. 1 Jianshe East, Zhengzhou, Henan, China
1 shared publicationHongwei Yang
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China
1 shared publicationHuanan Wang
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China
1 shared publication
Latest Publications
- 6 June 2025
- Published by Elsevier in Cellular Signalling
- Vol. 134, 111925
PRMT5-FOXM1 axis activates β-catenin/IL8 signaling to drive angiogenesis of gastric cancer
- 6 June 2025
- Published by Elsevier in Cellular Signalling
- Vol. 134, 111925
PRMT5-FOXM1 axis activates β-catenin/IL8 signaling to drive angiogenesis of gastric cancer
- 1 January 2020
- Vol. 10 (2) , 403-+
FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway
Chemoresistance is a leading cause of tumor relapse and treatment failure in colorectal cancer (CRC) patients and is correlated with epithelial-mesenchymal transition (EMT). This study was aimed to explore the mechanism of EMT in chemoresistant CRC. Bioinformatic method was used to screen differentially expressed genes between 5-FU sensitive and resistant CRC cells. Immunohistochemistry staining was utilized to analyze the expression of FLNA in CRC tissues. The roles of FLNA in chemoresistance were validated via loss-of-function and gain-of-function experiments in vitro and in an orthotopic CRC animal model. The regulation of c-Met signaling by FLNA was explored via Co-Immunoprecipitation and luciferase reporter assays. Our results suggested FLNA directly regulated the metastasis and EMT of chemoresistant CRC cells. Moreover, c-Met- AKT mediated ser2152 phosphorylation of FLNA was demonstrated to be correlated with EMT. In turn, FLNA enhanced c-Met promoter activity by its interaction with smad2. Clinically, the expression of FLNA was significantly associated with c-Met protein levels in CRC tissues. These data established that FLNA could be a novel and reliable CRC marker and a potential therapeutic target against CRC.
- 1 January 2020
- Vol. 10 (2) , 403-+
FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway
Chemoresistance is a leading cause of tumor relapse and treatment failure in colorectal cancer (CRC) patients and is correlated with epithelial-mesenchymal transition (EMT). This study was aimed to explore the mechanism of EMT in chemoresistant CRC. Bioinformatic method was used to screen differentially expressed genes between 5-FU sensitive and resistant CRC cells. Immunohistochemistry staining was utilized to analyze the expression of FLNA in CRC tissues. The roles of FLNA in chemoresistance were validated via loss-of-function and gain-of-function experiments in vitro and in an orthotopic CRC animal model. The regulation of c-Met signaling by FLNA was explored via Co-Immunoprecipitation and luciferase reporter assays. Our results suggested FLNA directly regulated the metastasis and EMT of chemoresistant CRC cells. Moreover, c-Met- AKT mediated ser2152 phosphorylation of FLNA was demonstrated to be correlated with EMT. In turn, FLNA enhanced c-Met promoter activity by its interaction with smad2. Clinically, the expression of FLNA was significantly associated with c-Met protein levels in CRC tissues. These data established that FLNA could be a novel and reliable CRC marker and a potential therapeutic target against CRC.